What are the recommended dosing, monitoring, and contraindications for potassium‑sparing diuretics such as spironolactone, eplerenone, amiloride, and triamterene?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 8, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Potassium-Sparing Diuretics: Dosing, Monitoring, and Contraindications

For aldosterone antagonists (spironolactone and eplerenone) in heart failure with reduced ejection fraction, start with 25 mg once daily, titrate to 50 mg daily after 4-8 weeks if tolerated, and monitor potassium and creatinine at 1 and 4 weeks after initiation or dose changes, then at 1,2,3, and 6 months after reaching maintenance dose. For amiloride and triamterene, use only when persistent hypokalemia occurs despite ACE inhibitor therapy, not as first-line agents 1.

Aldosterone Antagonists (Spironolactone and Eplerenone)

Indications and Evidence Base

Spironolactone and eplerenone are indicated for patients with LVEF ≤35% and NYHA class III-IV symptoms on optimal therapy with ACE inhibitor/ARB and beta-blocker (but not both ACE inhibitor AND ARB together) 1, 2. The RALES trial demonstrated spironolactone reduced mortality by 30% and heart failure hospitalizations by 35% in severe heart failure 1. EPHESUS showed eplerenone reduced mortality by 15% post-MI in patients with LVEF ≤40% 1.

Dosing Protocol

Starting dose:

  • Spironolactone: 25 mg once daily 1, 2, 3
  • Eplerenone: 25 mg once daily 1, 2, 4

Target dose:

  • Spironolactone: 50 mg once daily (maximum 100-200 mg daily in older guidelines, though 50 mg is the evidence-based target) 5
  • Eplerenone: 50 mg once daily 1, 4

Titration schedule: Consider dose increase after 4-8 weeks if no hyperkalemia or worsening renal function 1, 6.

Monitoring Requirements

Before initiation: Check serum potassium (must be <5.0 mEq/L) and renal function (creatinine clearance must be >30 mL/min) 1, 2, 4, 3.

After initiation/dose changes:

  • Check potassium and creatinine at 1 week and 4 weeks 1, 6
  • After reaching maintenance dose: check at 1,2,3, and 6 months, then every 6 months thereafter 1, 6

Management of Adverse Effects

Hyperkalemia:

  • If potassium >5.5 mmol/L: Halve the dose (e.g., 25 mg on alternate days) and monitor closely 1, 6, 1
  • If potassium ≥6.0 mmol/L: Stop immediately and treat hyperkalemia; monitor blood chemistry closely 1, 6, 1
  • If potassium cannot be maintained <5.5 mEq/L: Discontinue to avoid life-threatening hyperkalemia 2

Worsening renal function:

  • If creatinine >220 μmol/L (2.5 mg/dL): Halve the dose and monitor closely 1, 6
  • If creatinine >310 μmol/L (3.5 mg/dL): Stop immediately and monitor closely 1

Gynecomastia: Occurs in ~10% of men on spironolactone; switch to eplerenone if this develops 1, 6, 3.

Contraindications

Absolute contraindications for both agents:

  • Serum potassium >5.5 mEq/L (>5.0 mEq/L per newer guidelines) 2, 4, 3
  • Creatinine clearance ≤30 mL/min 1, 2, 4
  • Concomitant use with strong CYP3A inhibitors 4
  • Concomitant use with both ACE inhibitor AND ARB together 1

Additional contraindications for eplerenone in hypertension:

  • Type 2 diabetes with microalbuminuria 4
  • Serum creatinine >2.0 mg/dL in males or >1.8 mg/dL in females 4

Drug Interactions

With moderate CYP3A inhibitors (verapamil, erythromycin, fluconazole): Do not exceed 25 mg once daily in post-MI heart failure patients 4.

Amiloride and Triamterene

Indications

Use amiloride and triamterene ONLY when hypokalemia persists despite ACE inhibitor and diuretic therapy 5, 7, 5. These agents should NOT be used during ACE inhibitor initiation 5. They are NOT first-line agents for heart failure mortality reduction.

Dosing

Amiloride:

  • Initial: 2.5-5 mg once daily 5
  • Maximum: 20-40 mg daily 5

Triamterene:

  • Initial: 25-50 mg once daily 5
  • Maximum: 100-200 mg daily 5

Monitoring

Start with 1-week low-dose administration, check serum potassium and creatinine after 5-7 days, then recheck every 5-7 days until potassium values are stable 5, 7, 5. After stabilization, monitor every 3-6 months 5.

Contraindications for Amiloride

  • Hyperkalemia (potassium >5.5 mEq/L) 8
  • Concomitant potassium-sparing agents or potassium supplementation 8
  • Anuria or acute/chronic renal insufficiency 8
  • BUN >30 mg/100 mL or serum creatinine >1.5 mg/100 mL 8
  • Diabetic nephropathy 8

Critical Clinical Pitfalls

The combination of potassium-sparing diuretics with ACE inhibitors was historically considered dangerous, but controlled studies have shown this can be done safely with appropriate monitoring 5. However, hyperkalemia occurs more frequently in real-world practice than in clinical trials, especially in elderly patients 1.

Avoid NSAIDs during therapy as they increase hyperkalemia risk 5.

Do NOT use potassium supplements concurrently except in severe refractory hypokalemia with very close monitoring 8.

Relative potency for blood pressure reduction: Spironolactone > amiloride > eplerenone, with dose equivalencies of approximately eplerenone 125 mg = spironolactone 25 mg, and amiloride 3.3 mg = spironolactone 1 mg 9.

References

Related Questions

What is the appropriate starting dose and titration schedule of spironolactone for an adult patient with hypertension without severe renal impairment or baseline hyperkalemia?
Should spironolactone be held in a patient with an episode of tachycardia?
What alternative medications can be used instead of spironolactone for a male patient?
Can triamterene or amiloride be added to a regimen that includes spironolactone?
What is the recommended eplerenone dosing regimen, including initial dose and titration based on serum potassium levels and renal function?
For follow-up radiographs of a fibular shaft fracture at 12 weeks post-injury, should the images be obtained with weight-bearing?
In a 47-year-old man with total cholesterol 212 mg/dL, HDL cholesterol 28 mg/dL, triglycerides 670 mg/dL, hemoglobin A1c 5.9 %, glomerular filtration rate 98 mL/min, AST 24 U/L, and ALT 65 U/L, what is the appropriate starting dose of fenofibrate?
Can a hemostatic sponge be used as a suture material to close a wound?
For a newly diagnosed ADHD patient on immediate‑release Adderall who experiences extreme mood swings (high highs and low lows), what medication should be switched to?
What short‑acting benzodiazepine or alternative medication is appropriate for a generally healthy adult with acute flight‑related anxiety and no contraindications such as severe respiratory disease, severe liver impairment, glaucoma, pregnancy, or substance use disorder?
In a patient who experiences lightheadedness, dizziness, nausea, and headache upon standing, and who was started on lisinopril 10 mg orally daily and had his bupropion (Wellbutrin) increased from 300 mg to 450 mg, which medication is most likely causing these side effects?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.